Alliance Global Partners analyst James Molloy raised the firm’s price target on Akari Therapeutics (AKTX) to $7 from $4 and keeps a Buy rating on the shares. The firm cites its expectations for the company’s new antibody drug conjugate centered pipeline following its 2024 merger with Peak Bio for the target increase.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue